

CURRICULUM VITAE

SUNIL S. PATEL, MD, PHD
(April 2024)

Current (Past) Employment and Professional Activities

Staff Vitreoretinal Surgeon

Managing Partner and Founder (2000-Present)

Ophthalmology Specialist of Texas, PLLC (medical practice)

dba/West Texas Retina Consultants

dba/North Texas Retina Consultants

5441 Health Center Drive

Abilene, Texas 79606

(325) 673-9806

sunilpateltgo@gmail.com

Principal Research Investigator and President (2003-Present)

Integrated Clinical Research, LLC (clinical research center)

dba/Retina Research Institute of Texas

5441 Health Center Drive

Abilene, Texas 79606

(325) 690-4414

dr.patel@txicr.com

Chief Executive Officer and Founder (2007-Present)

Vision BioSciences, LLC

101 Chuckwagon Trail

Willow Park, Texas 76087

(817) 441-1212

Executive Director (2019-Present)

Clinical Research Management, LLC (site management organization - clinical research)

5401 US-277

Abilene, Texas 79606

(325) 690-4493

Managing Partner/Staff Surgeon (2009-Present)

Abilene Surgery Center, LLC (ambulatory surgery center)

5601 Health Center Drive

Abilene, Texas 79606

(325) 690-4466

Chief Executive Officer

GalenHealth, LLC

4224 South 20th Street

Abilene, Tx 79605

Chairman of the Board (2014-Present)

BraneSystems, LLC (AI and cloud-based healthcare security and technology company)
5401 US-277
Abilene, Texas 79606
(325) 690-4443

Assistant Clinical Professor (1998-2016)

Texas Tech University School of Medicine
Department of Ophthalmology
3601 4th St
Lubbock, Texas 79430
(806) 743-2020

Chief Medical Officer (7/2021-4/2024)

Allgenesis Biotherapeutics Inc.
Cell: 1-325-660-8984
9F.-3, No.760, Sec. 4, Chief Bade Rd., Songshan Dist., Taipei City 105, Taiwan (R.O.C.)

Current or Previous Consulting Experience

Consultant: AiViva BioPharma, Alcon, Allergan, Allgenesis Biotherapeutics, EyeTech, Genentech-Roche, Iveric Bio, Kala Pharmaceuticals, Kodiak Sciences, Novartis, Ocugenix, Ophthotech, RegenxBio

Advisory Board: Allergan, Allgenesis Biotherapeutics, Genentech-Roche, Iveric Bio, Kodiak Sciences, Ophthotech

Medical License

California: A051774
Texas: K4185
DEA: BP3670329
DPS: H0104495

Previous Employment

Vitreoretinal Surgeon-Texas Retina Associates, PA (9/1997 to 9/2000), Dallas, Texas

Clinical Instructor-Doheny Eye Institute (7/1996 to 08/1997), University of Southern California, Los Angeles, California

Education

Bachelor of Science (BS): University of California, Los Angeles (UCLA)
(*Biochemistry*) Los Angeles, California (9/1979-6/1983)

Doctor of Philosophy (PhD): University of Texas Southwestern Graduate School of Biomedical Sciences
(*Immunology*) Dallas, Texas (06/1985-8/1989)

Doctor of Medicine (MD): University of Texas Southwestern Medical School
Dallas, Texas (7/1983-5/1991)

Doctor of Philosophy Thesis

Advisor: Peter E. Lipsky, M.D. (6/1985-8/1989)
Date of Defense: 08/21/1989
Title: ***Functional and phenotypic analysis of human T cell clones***

Internship

Internal Medicine: Presbyterian Hospital of Dallas
University of Texas Southwestern Medical School (Affiliate)
Dallas, Texas (07/1991-06/1992)

Residency

Ophthalmology: Doheny Eye Institute-Los Angeles County Hospital (07/1992-06/1995),
University of Southern California, Los Angeles, California

Fellowships

Surgical and Medical Vitreoretinal Fellowship: Doheny Eye Institute-Los Angeles County Hospital
(7/1/1995-06/30/1996) University of Southern California, Los Angeles, California

Uveitis Fellowship: Doheny Eye Institute-Los Angeles County Hospital (07/01/1996-07/31/1997)
University of Southern California, Los Angeles, California

Additional Training

Director of Vitreoretinal Services at the USC- Los Angeles County Hospital (07/01/1996-07/31/1997)

Chief Resident at USC- Los Angeles County Hospital (07/01/1996-06/30/1997)

Ocular Oncology Training – A. Linn Murphree, MD at Doheny Eye Institute-USC School of Medicine (07/01/1995-06/30/1996)

Collaborative Ocular Melanoma Study (COMS) certification for the diagnosis and management of choroidal melanoma (07/01/1996-08/01/1997)

Investigator Education for the Protection of Human Research Subjects (12/04/2003)

Ophthalmology Board Certifications

Diplomate of the American Board of Ophthalmology (10/1996)

Diplomate of the American Board of Ophthalmology (Renewal 10/2006)

Diplomate of the American Board of Ophthalmology (Renewal 10/2016)

Professional Societies

American Academy of Ophthalmology

American Society of Retinal Specialists

American Uveitis Society

American Association of Immunologists

American Association for the Advancement of Science

Association for Research in Vision and Ophthalmology

International Society for Stem Cell Research

Alpha Omega Alpha National Medical Honor Society

Phi Beta Kappa

Texas Ophthalmological Association

Undergraduate Awards, Honors, and Fellowships

Dean's Honors List at UCLA

Marilyn F. Lohr Memorial Physics Scholarship

Departmental Honors in the Department of Chemistry and Biochemistry at UCLA

Magna Cum Laude

Phi Beta Kappa National Honor Society

Golden Key Honor Society

UCLA Summer Research Fellowship

American Heart Association Research Fellowship

Graduate Awards, Honors, and Fellowships

Southwestern Medical Foundation Scholarship
Medical Scientist Training Program (National Institutes of Health) MD/PHD Fellowship
Harold C. Simmons Research Fellowship
Alpha Omega Alpha Medical Honor Society

Post-Graduate Honors and Awards

Award for Excellence in Resident Training at the Doheny Eye Institute (1997)
American Academy of Ophthalmology Achievement Award (2009)
Texas Ophthalmological Association Council Member (2004-2010)
Texas Ophthalmological Association Past President (2011)
Scientific Reviewer for *Ophthalmology*
American Society of Retinal Specialists (ASRS) Honor Award (2023)

Research Interest

Regenerative medicine - reprogramming of cells for the management of retinal diseases
Cell functional dynamics and its role in biology and medicine
Cellular therapy in the management of retinal degenerative diseases
Molecular Mechanisms of immune regulation
Translational research -applications of new therapeutics for retinal degenerative diseases
New and innovative surgical therapies for management of retinal diseases
Efficient delivery of health care services in cost effective manner
Health Care's role and impact on financial productivity of patients
Artificial Intelligent (deep learning) and reinforcement learning systems for the management of vitreoretinal diseases

Publications/Manuscripts (Authored)

Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1987. Major histocompatibility complex-unrestricted cytotoxic activity of human T cells. Analysis of precursor frequency and effector phenotype. *J. Immunology*. 139:3886.

Thiele D.L., **S.S. Patel**, and P.E. Lipsky. 1988. Anti-CD3 and phorbol myristate acetate regulation of MHC unrestricted T cell cytotoxicity: Lack of a requirement for CD3/T cell receptor complex expression during tumor lysis. *J. Immunology*. 140:3253.

Davis, L.S., **S.S. Patel**, J.P. Atkinson, and P.E. Lipsky. 1988. Decay-accelerating factor functions as a signal transducing molecule for human T cells. *J. Immunology*. 141:2246.

Patel, S.S., A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1988. Phenotypic and functional characterization of human T cell clones. *J. Immunology*. 141:3726.

Geppert, T.D., M.C. Wacholtz, **S.S. Patel**, E. Lightfoot, and P.E. Lipsky. 1989. Activation of human T cell clones and Jurkat cells by cross-linking class I major histocompatibility complex molecules. *J. Immunol.* 142:3763.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. Patterns of co-stimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules. *J. Immunology*. 142:4201.

Patel, S.S. 1989. Functional and phenotypic analysis of human T cell clones. University of Texas Southwestern Medical School. Dissertation.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. LFA-1 is a signaling molecule for human T lymphocytes. In *Structure and function of molecules involved in leukocyte adhesion*. Eds. A.S. Rosenthal, T.A. Springer, D.C. Anderson, and R. Rothlein. Springer-Verlag. p.254-264.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. Leukocyte function-associated antigen 1 is an activation molecule for human T cells. *J. Exp. Med.* 170:431.

Patel, S.S., M.C. Wacholtz, A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1989. Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. *J. Immunology*. 143:1108.

Hirohata, **S.**, **S.S. Patel**, and P.E. Lipsky. 1990. Regulation of human B cell responsiveness by CD8+ T cells: Differential effects of stimulation with monoclonal antibodies to CD3 and pokeweed mitogen. *Cell. Immunology*. 127:35.

Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1993. Stimulus-dependent modulation of human B cell function by T cell clones. *Cell. Immunology*. 146:362.

Jou, J., **S.S. Patel**, C. Yo, A.A. Sadun. 1995. Orbital Coccidioidomycosis presenting as a lacrimal fossa mass. *Brit J. Ophthalmology*. 79:1145.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1996. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Ophthalmology*. 103:1476.

Marx, J.L., M.A. Kapusta, **S.S. Patel**, F. Walonker, N.A. Rao, and L.P. Chong. 1996. Use of the ganciclovir implant in the treatment of recurrent CMV retinitis. *Archives of Ophthalmology*. 114:815.

Johnston, R.H., R.L. Nguyen, A. Jongsareejit, B.R. Lee, **S. Patel**, and L. Chong. 1999. Clinical Study of combined penetrating keratoplasty, pars plana vitrectomy with temporary keratoprosthesis, and pars plana seton implant. *Retina* 19:116.

Boyer DS, Faber D, Gupta S, **Patel SS**, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM et al. 2011. Ozurdex CHAMPLAIN Study Group., for Retina-Vitreous Associates Medical Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. *Retina*. 31: 915-923.

Nguyen, QD, DM Brown, DM Marcus, DS Boyer, **S Patel**, L. Finer, A Gibson, AC Rundle, JJ Hopkins, RG Rubio, JS Ehrlich, and RISE and RIDE Research Group. 2012. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. *Ophthalmology*. 119:789-801.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, **Patel S**, Feiner L, et al. 2013. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials- RISE and RIDE. *Ophthalmology* 120:2013-2022.

Campochiaro PA, Khanani A, Singer M, **Patel S**, Boyer D, Dugel P, et al. 2016 Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. *Ophthalmology* 123: 1722-1730

Callanan DG, Loewenstein A, **Patel SS**, Massin P, Corcóstegui B, Li XY, Jiao J, Hashad Y, Whitcup SM. 2017. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol* 255:463-473.

Callanan D, Kunimoto D, Maturi RK, **Patel SS**, Staurengi G, Wolf S, Cheetham JK, Hohman TC, Kim K, López FJ, Schneider S. 2018. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPIn Therapeutic) in Neovascular Age-Related Macular Degeneration. *J Ocul Pharmacol Ther*. 34:700-709.

Sahni J, **Patel SS**, Dugel PU, Khanani AM, Jhaveri JD, Wykoff CC. 2019. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. *Ophthalmology* 126:1155–1170

Heier JS, Pieramici D, Chakravarthy U, **Patel SS**, Gupta S, Lotery A, Lad EM, Silverman D, Henry EC, Anderesi M, Tschosik EA, Gray S, Ferrara D, Guymer R. 2020. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. *Ophthalmology Retina* 4:673–688.

Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, **Patel SS**, et al. 2020. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. *Ophthalmology* 128: 576–586.

Heier JS, Wykoff CC, Waheed NK, Kitchens JW, **Patel SS**, Vitti R, et al. 2020. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. *Ophthalmology* 127: 211–220.

Khanani AM, **Patel SS**, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. 2020. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular

Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. *JAMA Ophthalmol.* 138:964-972.

Sahni J, Dugel PU, **Patel SS**, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S. 2020. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. *JAMA Ophthalmol.* 138:955-963.

Kuppermann BD, **Patel SS**, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, López FJ; Brimo DDS Gen 1 Study Group. 2021. Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. *Retina.* 41:144-155.

Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, **Patel SS**, Joondeph BC, Randolph J, Masonson H, Rezaei KA. 2021. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. *Ophthalmology.* 128:576-586.

Khanani AM, **SS Patel**, VH Gonzalez, SJ Moon, GJ Jaffe, JA Wells, P Kozma, PU Dugel, RK Maturi. 2021. Phase 1 Study of THR 687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema. *Ophthalmology Science.* 1:100040.

Dugel PU, AM Khanani, B Berger, **S Patel**, M Fineman, GJ Jaffe, P Kozma, J Heier. 2021. Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema. *Translational Vision Science and Technology.*10:28.

Patel SS, DR Lally, J Hsu, CC Wykoff, D Eichenbaum, JS Heier, GJ Jaffe, K Westby, D Desai, L Zhu, AM Khanani. 2023. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. *Eye.* DOI: 10.1038/s41433-023-02497-w

Freeman WR, F Bandello, E Souied, RH Guymer, SJ Garg, FK Chen, R Rich, FG Holz FG, **SS Patel**, K Kim, FJ López on behalf of the BEACON Study Group. 2023. Randomized Phase 2b Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-related Macular Degeneration *Ophthalmology Retina (Accepted).*

Khanani AM, **SS Patel**, G Staurengi, R Tadayoni, CJ Danzig, DA Eichenbaum, J Hsu, CC Wykoff,

JS Heier, DR Lally, J Monés, JS Nielsen, VS Sheth, PK Kaiser, J Clark, L Zhu, H Patel, J Tang, D Desai, GJ Jaffe, on behalf of the GATHER2 trial investigators. 2023. Efficacy and Safety of Avacincaptad Pegol for Geographic Atrophy: 12-Month Results From the GATHER2 Randomised Phase 3 Trial. *Lancet*. [https://doi.org/10.1016/S0140-6736\(23\)01583-0](https://doi.org/10.1016/S0140-6736(23)01583-0).

Callanan D, RN Khurana, R Maturi, **S Patel**, CC Wykoff, D Eichenbaum, A M. Khanani, T Hassan, H Badger, S Mehta, G Le M Attar, XY Li. 2023. Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results. *Journal of Clinical Ophthalmology*. DOI <https://doi.org/10.2147/OPHTH.S405994>.

Bressler SB, A Barve, K Beckman, RS Apte, DM Marcus, K Bauman, S Agarwal, Y San, P Oleksy, DA Reichstein, **SS Patel**, DV Alfaro, J Ernest, R Degi, V Gupta, G Kishino, M Kame, P Oleksy, A Jagatheesan, P C Ganapathi. 2023. Efficacy and Safety of Biosimilar MYL-1701P Compared with Reference Aflibercept (Eylea®) in Diabetic Macula Edema: One-Year Outcomes of a Phase 3 Study. *JAMA Ophthalmology* (Submitted)

Patel S, P Storey, M Barakat, V Hershberger, W Bridges, D Eichenbaum, D Lally, D Boyer, S Bakri, M Roy, and D Paggiarino. 2024. Phase 1 DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients with Wet Age-related Macular Degeneration. *Ophthalmology Science*. 100527. <https://doi.org/10.1016/j.xops.2024.100527>.

Retina Research Institute of Texas-Clinical Research Studies

Principal Investigator, **Adverum Biotechnologies, Inc. ADVM-022-01/ORA STUDY #17120-0013**, “An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration – [OPTIC]” (April 2020– March 2021)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **Adverum Biotechnologies, Inc. INFINITY ADVM-022-04**, “ADVM-022-04: Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema (DME)” (June 2020 –March 2021)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **Aerie Pharmaceuticals, Inc. AR-13503-CS201**, “First in Human Study of Safety of AR-13503 sustained release intravitreal implant in subjects with neovascular age related macular degeneration (nAMD) and subjects with Diabetic Macular Edema (DME)” (Feb 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **AiViva Biopharma Inc. AI007-E01-00**, “A Phase I Study of the Safety, Pharmacokinetics, and Duration of Effect of Intravitreally Administrated AIV007 Gel Suspension in Subjects with Neovascular Age-Related Macular Degeneration” (June 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Amgen, Inc. 20170542**, “A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration (hereinafter“Protocol”) ABP 938 (hereinafter “Study Drug”).” (June 2020–Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **AsclepiX Therapeutics Inc. AXT107-CS101 Congo**, “Phase 1/2a Study of the Safety of AXT107 in Subjects with Diabetic Macular Edema (DME)” (Jan 2021–Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **AsclepiX Therapeutics Inc. AXT107-CS102 Shasta**, “Phase 1/2a Study of the Safety of AXT107 in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)”
(March 2021–Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Boehringer Ingelheim Pharmaceuticals, Inc. 1336-0007**, “Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD” (August 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Boehringer Ingelheim Pharmaceuticals, Inc. 1436-0001 Hornbill** , “HORNBILL: A study to test different doses of BI 764524 in patients who have had laser treatment for a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia” (August 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Eyepoint Pharmaceuticals, Inc. EYP-1901-001** “A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with wet AMD” (Dec 2020 – Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Eyevensys Inc. EYS606-CT2**, “A 48 Week Phase II, Randomized, open-label, multicenter, study to evaluate the efficacy and safety of Two (2) EYS606 Treatment Regimens in Subjects

with Active Chronic Non-infectious Uveitis (CNIU)” (May 2020– March 2021)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Gemini Therapeutics, Inc. GEM-CL-10302**, “A Multicenter, Open label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections” (Sept 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Genentech, Inc. GR41984 Balaton**, “A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion” (July 2020 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Genentech, Inc. GR41986 Comino**, “A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion” (July 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Genentech, Inc. GR41675 Pavilion**, “A Phase III, multicenter, randomized study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic retinopathy.” (June 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Genentech, Inc. GR42691 Avonelle**, “A multicenter, open label extension study to evaluate the long term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration” (April 2021– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Genentech, Inc. GR41987 Rhone X**, “A multicenter, open-label extension to evaluate the long term safety and tolerability of faricimab in patients with Diabetic Macular Edema” (September 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Graybug Vision, Inc. GBV-102-002 Altissimo**, “A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot

Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (Altissimo Study)” (May 2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **IVERIC Bio, Inc. ISEE2008**, “A phase 3 clinical study to further test the safety and efficacy of its proprietary drug candidate known as ZIMURA (avacincaptad pegol) in patients with geographic atrophy secondary to dry age-related macular degeneration.” (March 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Kodiak Sciences, Inc. KS301P103 BEACON**, “A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)” (Sept 2020– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Kodiak Sciences, Inc. KS301P105 Glimmer**, “A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)” (Sept 2020–Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Outlook Therapeutics, Inc. ONS-5010-003 Norse 3**, A 3-month study to assess the safety of ONS-5010 in subjects with visual impairment due to retinal disorders, Norse three.” (Sept 2020– March 2021)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Oxurion NV THR-149-002**, “A Phase 2, randomized, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME)” (August 2020 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Regeneron Pharmaceuticals VGFTe(HD)-AMD-1905 Candela**, “A randomized, Single-Masked, Active-Controlled Phase 2 Study of the safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration” (Dec 2019– Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Regeneron Pharmaceuticals VGFTe-HD-DME-1934 Photon**, “A Randomized, double-masked, active-controlled Phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema- PHOTON” (July 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **Roche TCRC, Inc. BP41321 Canberra**, “A randomized, double-masked, 48-week, parallel-group, Placebo controlled, Proof of Concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve Diabetic Retinopathy”
(Feb 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Roche TCRC, Inc. GR40550 Pagoda**, “A phase III, multi-center, randomized, visual assessor-masked, active comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema (Pagoda)” (Jan 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator , **Sam Chun Dang Pharm. Co., Ltd. SCD411-CP101**, “A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration” (Sept 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **Samsung Bioepis Co., Ltd. SB15-3001**, “A phase III randomized, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB15 (proposed aflibercept biosimilar) and Eylea in subjects with neovascular age-related macular degeneration” (May 2020– Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **ThromboGenics, Inc. THR-687-001**, “A Phase I, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME)” (Aug 2018 – Feb 2020)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, **Apellis APL2-303 Derby**, “A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with

Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Apellis APL2-304 Oaks, “A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Boehringer Ingelheim Pharmaceuticals, Inc. 1418-0001, “Safety, tolerability and pharmacokinetics of single rising intravitreal doses of BI 754132 in patients with geographic atrophy secondary to age-related macular degeneration (open label, nonrandomized, uncontrolled).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Genentech Lucerne GR40844, “A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration (Lucerne).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Genentech Gallego GR40973, “A Phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration (GALLEGO).” (2019 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, Graybug Vision, Inc. GBV-102-002 Altissimo, “A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (Altissimo Study).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Ionis Pharmaceuticals, Inc. ISIS 696844-CS5, “A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Kodiak Sciences, Inc. KSI-CL-102, “A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subject with Neovascular (Wet) Age-related Ocular Degeneration.” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Neurotech Pharmaceuticals, Inc. NTMT03-B, “A Phase III multicenter Randomized, Sham Controlled, Study to determine the safety and efficacy of Renexus in Macular Telangiectasia Type 2.” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Novartis RTH258B2305 Kingfisher, “A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema (Kingfisher).” (2019 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Sub-Investigator, Novartis RTH258B2301 Raptor, “An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion (RAPTOR).” (2019 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Sub-Investigator, Novartis RTH258B2302 Raven, “An Eighteen-month, Two-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN).” (2019 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Sub-Investigator, Novartis RTH258A2309, “A Single-Arm, Open-Label, Multicenter, Phase IIIb Study to Collect Safety and Electrocardiogram Data on Brolucizumab 6mg Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration.” (May 2019 – September 2019)

Principal Investigator: Grant P. Janzen, M.D

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Outlook Therapeutics, Inc. ONS-5010-002, “A Clinical Effectiveness, Multi-center, Randomized, Double-Masked, Controlled Study of the efficacy and safety of ONS-2010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) to Secondary to Age-Related Macular Degeneration (AMD).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Roche TCRC, Inc. Dovetail BP40899, “A multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200220 in Mono-therapy and in combination with ranibizumab following intravitreal administration in patients with diabetic macular edema.” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Roche TCRC, Inc. Bluetail BP40923, “A multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200394 following intravitreal administration in patients with neovascular age-related macular degeneration.” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Stealth Bio Therapeutics, Inc. SPIAM-202 / ORA Study #18-120-0012, “A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy.” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Xbrane Biopharma XBR1001 Xplore, “Xplore: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration.” (2019 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, Aerie Pharmaceuticals, Inc., “A multicenter, open-label study safety and proof-of-concept study to assess safety, tolerability and efficacy of AR-1105 in subjects with macular edema due to retina vein occlusion, AR-1105 (dexamethasone) implant for intravitreal administration).” (2019 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Novartis, Merlin CRTH258AUS04, “A multicenter, randomized, double-masked Phase 3a study to assess the safety and efficacy of brolucizumab, 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with Neovascular age-related macular degenerations (nAMD) with persistent retina fluid (MERLIN.)” (November 2018 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, Genentech Yosemite GR40349, “A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic, macular edema (YOSEMITE.)” (November 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Chengdu Kanghong Biotechnology Co., Ltd. Panda KHB-1801, “A multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.” (October 2018 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, Genentech Stairway CR39521, “Stairway: Simultaneous blockade of Angiopoietin-2 and VEGF with the bispecific antibody RO6867461 (RG7716) for extended durability in the treatment of Neovascular Age-Related Macular Degeneration.” (February 2017 – June 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Ora Graybug GBV-102-001, “A Phase 1 / 2 Multicenter Study Evaluating the Safety, Tolerability and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-related Macular Degeneration.” (August 2017 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Ora Kalvista KVD001-201, “A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti vascular endothelial growth factor (VEGF).” (February 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, ThromboGenics THR-149-001, “A multi-center study under protocol entitled A Phase I, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injections of THR-149 for the treatment of Diabetic Macular Edema (DME).” (May 2018 – Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Boehringer Ingelheim Pharmaceuticals, Inc. Robin 1386.12, “A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 without center-involved Diabetic Macular Edema.” (May 2018 – Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Trial Runners Aerpio AKB-9778, “Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15MG once daily or 15 MG twice daily for 12 months in patients with moderate to severe Non-Proliferative Diabetic Retinopathy.” (November 2017 – Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Samsung SB11-G31-AMD, “A Phase II randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis in subjects with Neovascular Age- Related Macular Degeneration.” (March 2018 – Present)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, Clearside Tybee CLS1004-201, “Tybee: randomized, double masked, controlled study comparing the safety and efficacy of suprachoroidal CLS-TA with intravitreal aflibercept versus aflibercept alone in subjects with Diabetic Macular Edema.” (July 2017 – May 2018)
Principal Investigator: Eric Zavaleta, M.D.
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Sub-Investigator, Clearside Sapphire CLS1003-301, “A randomized, masked, controlled study the safety and efficacy of suprachoroidal CLS-TA in conjunction with Intravitreal Aflibercept in the subjects with Retinal Vein Occlusion.” (February 2017 – Present)
Principal Investigator: Eric Zavaleta, M.D.
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, Ophthotech Zimura OPH2007, “A phase 2a open –label trail to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5mg in treatment naïve subjects with Neovascular Age Related Macular Degeneration.” (September 2017 – October 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Opthea Ltd. 302-1002 WetAMD, “A dose ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in patients with Neovascular Age-Related Macular Degeneration (Wet AMD).” (December 2017 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Opthea Ltd. 302-1003 DME, “Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent Central-Involved Diabetic Macular Edema.” (January 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Sub-Investigator, InSite Vision, Inc. C-12-305-001, “A Phase 3, multicenter, randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of ISV-305 (0.1% Dexamethasone) compared to vehicle in the treatment of subjects with Blepharitis.” (March 2018 – Present)

Principal Investigator: Eric Zavaleta, M.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Charles L. Clark, M.D.

Principal Investigator, SciFluor SF0166-C-002, “A Phase I/II randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in the treatment of Neovascular Age-Related Macular Degeneration (AMD).” (October 2016 – October 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Allergan Maple 1771-201-008, “Evaluation of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.” (June 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Ora ProDex TLC399A2002, “A Phase IIa Trial of TLC399 (ProDex) in Subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability.” (April 2017 – Present)

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Alcon Hawk Extension CRTH258A2301E1, “A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolocizumab 6mg drug product intended for commercialization in patients with Neovascular age-related macular degeneration who have completed the CRTH258A2301.” (February 2018 – October 2018)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Kodiak Sciences Inc. KSI-CL-101, “A Phase I open label, multi-center study to investigate ocular and systemic safety, tolerability, and pharmacokinetics following a single intravitreal administration of KSI-301 in subjects with center involved diabetic macular edema (DME).”

(June 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Tryogenix Xcovery II X82-OPH-201, “A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea compared to prn Eylea monotherapy in Neovascular AMD.” (February 2016 – January 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Thrombogenics THR-687-001, “A Phase I, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME).” (September 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Mylan Inc. MYL-1701P, “A Multicenter, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects with Diabetic Macular Edema.” (August 2018 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D., Charles L. Clark, M.D.

Principal Investigator, Genentech Omaspect GX30191, “A Multicenter, Open-Label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic Atrophy secondary to age-related Macular Degeneration who have completed a Roche sponsored study.”

(July 2016 – April 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Ora Acucela 4429-203, “A multi-center, randomized, double-masked, placebo-controlled, pilot study to evaluate effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers associated with Proliferative Diabetic Retinopathy.” (April 2016 – January 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Regeneron Ruby R910-3-DME-1518, “A randomized, double-masked, active-controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Diabetic Macular Edema.”(March 2016 – December 2017)

Principal Investigator: Eric Zavaleta, M.D.

Sub Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Genentech Boulevard BP30099, “A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Diabetic Macular Edema.” (February 2016 – February 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Genentech Chroma GX29176, “A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to age-related Macular Degeneration.” (February 2016 – May 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Regeneron Onyx R910-3-AMD-1517, “A randomized, double masked, active controlled Phase II study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with Neovascular age-related Macular Degeneration.” (February 2016 – December 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Ophthotech Zimura OPH2003, “A Phase II/III randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura (Anti-C5 Aptamer) in subjects with Geographic Atrophy secondary to dry age-related Macular Degeneration.” (November 2015 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Regeneron Panorama VGFTe-OD-1411.02, “A Phase III, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe non-proliferative Diabetic Retinopathy.”(October 2015 – Present)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Daiichi Sankyo Pharma DS7080-A-U101, “Phase I dose escalation and expansion study of DS-7080a in subjects with Neovascular age-related Macular Degeneration.”

(October 2015 – April 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Opthea OPT-302, “A Phase I dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of OPT-302 in combination with Ranibizumab in subjects with Wet AMD.” (October 2015 – Apr 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Apellis Filly POT-CP121614, “A Phase II, multicenter, randomized, single-masked, Sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 Therapy in patients with Geographic Atrophy (GA).” (September 2015 – April 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Allegro PVD-202, “A Phase II, randomized, double-masked, placebo-controlled multicenter clinical trial designed to evaluate the safety and efficacy of Luminate in inducing PVD in subjects with Non-Proliferative Diabetic Retinopathy.” (June 2015 – October 2017)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Genentech Avenue BP29647, “A multi-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Choroidal Neovascularization secondary to age-related Macular Degeneration.”

(June 2015 – October 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Ophthotech OPH1004, “A Phase III randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (Anti PDGF-B Pegylated Aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with Subfoveal Neovascular age-related Macular Degeneration.”

(April 2015 – October 2016)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.

Principal Investigator, Allergan CEDAR 150998-005, “Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration-CEDAR STUDY.”

(May 2015 – 2020)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Regeneron Pharmaceuticals, Inc.-R2176-3-AMD-1417, “A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in patients with Neovascular Age-Related Macular Degeneration.”

(February 2015 – May 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, F. Hoffmann-La Roche, LTD-GX29639 Proxima, “A Multicenter, Prospective Epidemiologic Study of the Progression of Geographical Atrophy Secondary to Age-Related Macular Degeneration.” (January 2015 – January 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Sub-Investigator, University of Virginia (Paul Yates), TOGA-01, “A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographical Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.” (April 2015-Present)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Allegro Ophthalmics, LLC DME 202B, “A Phase II Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) As Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema.” (December 2014 –June 2017)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Eric Zavaleta, M.D

Sub-Investigator, ALCON RTH258-C001, “A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration.” (February 2015 – May 2018)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D

Principal Investigator, Astellas Pharma Europe- 8232-CL-3001, “A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema.” (January 2015 – December 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, XcoveryVision-X82-OPH-201, “A Randomized, Double-Masked, Placebo-Controlled, Dose Finding, Non-Inferiority Study of X-82 plus prn Eylea® Compared to prn Eylea® Monotherapy in Neovascular AMD.” (2015 – February 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Sub-Investigator, Ophthotech Corp.-OPH1006, “Effect of Anti-VEGF Agents Administered on a Quarterly Maintenance Regimen in Subjects with Neovascular AMD Receiving Anti-PDGF Therapy: An 18 Month Phase 2A Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination with Fovista® (Anti-PDGF BB Pegylated Aptamer).” (January 2015 – January 2017)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.

Principal Investigator, F. Hoffmann-La Roche, GX29639 Exposure, “A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients with Geographical Atrophy.” (November 2014 – October 2017)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, F. Hoffmann-La Roche, Spectri GX29185, “A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographical Atrophy Secondary to Age-Related Macular Degeneration.” (August 2014 – April 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Allergan 190342-038 BEACON, “Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographical Atrophy Secondary to Age-Related Macular Degeneration.” (November 2013 –October 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Ophthotech OPH1005, “Sub-Retinal Fibrosis in Neovascular AMD: A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regimen Administered in Combination with Anti-VEGF Therapy (Avastin®, Eylea®, or Lucentis®) During the Induction and Maintenance Phase of Therapy.” (June 2014 – January 2015)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, MD, Eric Zavaleta, M.D.

Sub-Investigator, Ophthotech OPH1002, “A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis® Monotherapy in subjects with Subfoveal Neovascular Age-Related Macular Degeneration. (August 2013 – March 2017)

Principal Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D., Eric Zavaleta, M.D.

Principal Investigator, Genentech OLEi GX28198, “A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of FCFD4514S in patients with Geographical Atrophy” (April 2012 – May 2018)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Iconic Therapeutics IT-002, “A Phase II randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1 in patients with Choroidal Neovascularization secondary to age-related Macular Degeneration.”

(June 2015 – November 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Genentech Ladder GX28228, “A Phase II, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the Ranibizumab port delivery system for sustained delivery of Ranibizumab in patients with Subfoveal Neovascular age related Macular Degeneration.”

(May 2015 – October 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, ALCON LMG324-2201, “An Open-Label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects with Neovascular age-related Macular Degeneration.” (2015 – June 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, ALCON-LHA510-2201, “A randomized, Double-Masked, Vehicle Controlled, Proof-of Concept Study for Topically Delivered LHA510 as a Maintenance therapy in patients with Wet Age-Related Macular Degeneration.” (2015 – September 2015)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Regeneron Pharmaceutical, Inc.-R910-3-OD-1403.01, “An Open-Label, Dose Escalation study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with either Neovascular AMD or DME.” (2015 – November 2015)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, Clearside Biomedical, Inc., CLS1003-201 Tanzanite, “Safety and Efficacy of Suprachoroidal CLS-TA in Combination with Intravitreal Aflibercept in Subjects with Macular Edema Following Retinal Vein Occlusion.” (2015 – April 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

Principal Investigator, National Eye Institute, National Institutes of Health, Department of Health and Human Services-SCORE2, “Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2): A Multicenter, Prospective, Randomized, Phase III, Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal Aflibercept Every 4 Weeks.” (2014 – January 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, MD, Eric Zavaleta, M.D.

Principal Investigator, PanOptica, Inc. PAN-01-101, “A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD).” (2014 – March 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Regeneron RE-VIEW VGFTe-AMD-1124, “An Open-Label Study of the efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-EYE (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.” (February 2013 – November 2015)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, GlaskoSmithKline BAM114341, “A Phase II, Multi-Centre, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).” (February 2011 – 2016)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Sub-Investigator, Regeneron Vista VGFT-OD-1009, “A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema.” (February 2011 – 2015)

Primary Investigator: Grant P. Janzen, M.D.

Sub-Investigator: S. Young Lee, M.D.,

Principal Investigator, **Lpath NEXUS LT1009-Oph-003**, “A phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSonep™ (Sonepcizumab [LT1009]) As either Monotherapy or adjunctive Therapy to Lucentis® or Avastin® Alone for the treatment of subjects with choroidal Neovascularization Secondary to Age-Related Macular Degeneration.” (July 2011 – 2015)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Xcovery Vision, LLC. X82-OPH-102**, “A Phase 1/2 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 administered per Os on Subjects with Neovascular Age-related Macular Degeneration (AMD).” (May 2013 – July 2015)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Ampio Pharmaceuticals, Inc. AP-05-002**, “A Randomized, Placebo Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in adult Patients with Diabetic Macular Edema.” (July 2013 – 2015)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **StemCells, Inc. CL-N01-AMD**, “Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-Sc) Subretinal Transplantation in Subjects with Geographical Atrophy of Age-Related Macular Degeneration.” (January 2014 – 2016)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Allergan 190342-033D**, “A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the biodegradation of the brimonidine Tartrate Posterior Segment Drug Delivery System.” (August 2010 – 2014)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Allergan REACH AGN-150998**, “Single and Repeat Dose of the Safety and Efficacy of AGN-150998 in patients with Exudative Age-related Macular Degeneration” (July 2011 – 2014)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Regeneron VIBRANT VEGFe-RVO-1027**, “A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion.” (May 2012 – 2014)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Alcon Research, Ltd. C-13-001, “A Prospective, Two-Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection of Infusion in Subjects with Exudative Age-Related Macular Degeneration.” (July 2013 – February 2014)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Allergan 206207-024, “A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema” (February 2012 – March 2014)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, DRCR Protocol N, “An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.” (July 2010 – 2016)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Novartis CLFG316A2202, “A Multicenter, Randomized, Sham-Controlled, Repeat-Dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients with Neovascular Age-Related Macular Degeneration.” (February 2012 – December 2013)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Alimera FAME C-01-11-008, “An Open Label, Multi-center Extension Study of the Safety and Utility of the New Insert of Iluvien® (Fluocinole Acetonide Intravitreal Insert) 0.19mg and the Safety of Iluvien in subjects with Diabetic Macular Edema.” (March 2011 – November 2013)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Allergan BDP 208397-001, “A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO).” (April 2011 – May 2013)
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, Pfizer B1181002, “A Phase I, Double-masked, Placebo-controlled study evaluating the Safety and Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G (PF-04382923) in subjects with Advanced Dry, Age-Related Macular Degeneration (AMD) including Geographical Atrophy.” (February 2010 – March 2013)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Pfizer B1181003, “A Phase 2 Multi-Center, Randomized, Double-Masked Placebo-Controlled, Multi-Dose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RN6G (PF-04382923) In Subject with Geographic Atrophy Secondary to Age-Related Macular Degeneration.”

(October 2012 – April 2013)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Genentech SHORE FVF4967g**, “A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab in Subjects with Macular Edema Following Retinal Vein Occlusion.” (February 2011 – January 2013)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Genentech FVF4168g RIDE**, “A phase III, double-masked, multicenter, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus.”

(April 2007 – December 2012)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Lpath Incorporated LT1009-OPH002**, “A Phase 1B Multicenter, Open-Label and Randomized study of ISONEP (Sonopvizumab/LT1009) administered as Intravenous Injections to subjects with PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy.” (March 2011 – November 2012)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Genentech FVF4579g Harbor**, “A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the efficacy and safety of 0.5mg and 2.0 mg Ranibizumab administered monthly or on an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-related Macular Degeneration.” (June 2009 – September 2012)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Sub-Investigator, **Alcon C-08-36 (GATE)**, “The safety and efficacy of AL-8309B ophthalmic Solution for the treatment of Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).”

(February 2009 – September 2012)

Principal Investigator: S. Young Lee, M.D.

Principal Investigator, **Regeneron VGFT-OD-0819**, “A Randomized, Double Masked, Controlled Phase III Study of the efficacy, safety and tolerability of repeated intravitreal administration of VEGF-Trap in subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).”

(August 2009 – June 2012)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Genentech Mahalo CFD4870g**, “A Phase Ib/II, Multicenter, Randomized, Single Masked, Sham-Injection-Controlled study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered monthly or Every other month to patients with Geographical Atrophy.” (December 2010 – April 2012)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Ophthotech OPH1001**, “A PHASE 2, Randomized, Double-Masked, Controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (Anti-PDGF Pegylated Aptamer) given in combination with Lucentis® in subjects with Neovascular Age-Related Macular Degeneration.” (March 2010 – March 2012)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Ophthotech OPH3000ss**, “A phase I ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetics profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (October 2010 – December 2011)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Victor Gonzales, M.D., PRESERVE**, “Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease.” (June 2010 – December 2011)

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

Principal Investigator, **Allergan 190342-031D-01**, “A Multicenter, Masked, Randomized, Sham Controlled, Parallel-group, 3-month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in improving Visual Function in patients with a previous Rhegmatogenous Macular-Off Retinal Detachment.”

(October 2009 – December 2011)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **DRCR Protocol O**, “Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema.” (August 2009 – October 2011)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Allergan 190342-032D-01**, “A Multicenter, Masked, Randomized, Sham-controlled, Paired-eyed Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System

(Brimonidine Tartrate PS DDS) Applicator system in Patients with Geographical Atrophy from Age-Related Macular Degeneration.” (June 2008 – August 2011)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Regeneron VGFT-OD-0605**, “A randomized, double-masked, active controlled Phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with Neovascular Age-Related Macular Degeneration.” (July 2007 – August 2011)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Alcon C-09-023 (Waltz)**, “A dose-escalated study of AL-39324 Suspension versus Lucentis® for the treatment of Exudative Age-Related Macular Degeneration.”
(November 2009 – June 2011)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Ophthotech OPH2001**, “A Phase I study to establish the safety and tolerability of ARC1905 (ANTI-C5 APTAMER) in subjects with Dry Age-Related Macular Degeneration.”
(June 2009 – June 2011)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Alimera Sciences C01-05-001**, “A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5µg/day and ASI-001B 0.2µg/day Fluocinolone Acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema.” (April 2006 – February 2011)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Regeneron VGFT-OD-0706**, “A Double-Masked, Randomized, Controlled study of the safety and efficacy, Tolerability and Biological effect of repeated Intravitreal Administration of VEGF-Trap in patients with Diabetic Macular Edema (DME).” (February 2009 – January 2011)
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Genentech FVF3426g HORIZON**, “An open-label, Multicenter extension study to evaluate the safety and tolerability of Ranibizumab in subjects with Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have completed a Genentech-sponsored Ranibizumab study.”
(June 2008 – October 2010)
Principal Investigator: S. Young Lee, M.D.

Principal Investigator, Allergan 206207-018, “A 26-week, Open-Label study to assess the safety and efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the treatment of Vitrectomized subjects with Diabetic Macular Edema.” (December 2008 – July 2010)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Allergan 206207-019, “A 26-week, Open Label study to assess the safety and efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® in the treatment of subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.” (December 2008 – July 2010)
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Allergan 206207-012-00, “A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema (DME).” (April 2007 – May 2010)
Principal Investigator: S. Young Lee, M.D.

Principal Investigator, Ophthotech OPH3000, “A phase I ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetics profile of multiple intravitreal injections of Volociximab (α5β1 integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (July 2008 – May 2010)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Ophthotech OPH2000, “A Phase 1, Ascending Dose and Parallel Group Trial to establish the Safety, Tolerability and Pharmacokinetic Profile of Multiple Intravenous Injections of ARC1905 (ANTI-C5 APTAMER) Given either in combination therapy with multiple doses of Lucentis® 0.5 mg/eye, or with one induction dose of Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (June 2008 – May 2010)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Ophthotech OPH1000, “A Phase I, single ascending dose trial to establish the safety, tolerability and pharmacokinetic profile of intravitreal injection of E10030 (Anti-PDGF Pegylated Aptamer) monotherapy and of E10030 given in combination with Lucentis 0.5 Mg/eye in subjects with

Neovascular Age-Related Macular Degeneration.” (November 2007 – May 2010)
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Genentech FVF4166g CRUISE**, “A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion.” (April 2007 – May 2010)
Principal Investigator: S. Young Lee, M.D.

Sub-Investigator, **Genentech FVF4165g BRAVO**, “A phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion.” (April 2007 – February 2010)
Principal Investigator: S. Young Lee, M.D.

Principal Investigator, **Jerini J0642701**, “A Phase I open-label study to investigate the safety, tolerability and pharmacokinetic profile of single and repeated doses of JSM6427 following administration by intravitreal injection in patients with Neovascular Age-Related Macular Degeneration.”
(September 2007 – September 2009)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **ALCON C-06-30**, “The Natural History of Geographical Atrophy Progression (GAP) Secondary to Age-Related Macular Degeneration (AMD).” (August 2008 – August 2009)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **OPKO ACU301C**, “A Phase 3, Randomized, Double-masked, Parallel-assignment study of Intravitreal Bevasiranib Sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD).” (July 2007 – July 2009)
Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **The Standard Care vs. Corticosteroid for Retina Vein Occlusion (SCORE) Study**, “Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injections of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion.” (August 2004 – June 2009)
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Allergan 206207-016, “A 6-Month, single- masked, multicenter, randomized, controlled study to assess the safety and efficacy of 700µg Dexamethasone posterior segment drug delivery system applicator system as adjunctive therapy to Lucentis compared with Lucentis alone in the treatment of patients with Choroidal Neovascularization secondary to Age-Related Macular Degeneration.”

(August 2007 – May 2009)

Principal Investigator: S. Young Lee, M.D.

Principal Investigator, Allergan SIRIUS, “A 2- year, Multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN 211745 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration”

(April 2007 – May 2009)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Allergan 206207-009-01, “A six-month, phase III, multicenter, masked randomized, sham-controlled trial (with six0month open label extension) to assess the safety and efficacy of 700µg and 350µg dexamethasone Posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion.” (February 2006 – March 2009)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, ALCON C0459, “Anecortave Acetate 15mg administered every 3 months versus Anecortave Acetate 15mg administered every 6 months versus Anecortave Acetate 30mg administered every 6 months in patients with exudative age-related macular degeneration.” (May 2005 – November 2008)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Eyetech 1023, “A phase IV, multi-center trial of maintenance intravitreal injections of Macugen®(Pegaptanib Sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with modality resulting in maculopathy improvement.” (June 2006 – October 2008)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, Anecortave Acetate Risk-Reduction Trial (AART) C-02-60, “Multicenter, double-masked, randomized, parallel groups clinical trial to demonstrate that Anecortave Acetate is safe and effective versus sham in arresting the progression of non-exudative AMD in patients who are at-risk for progressing to exudative AMD.” (August 2004 – October 2008)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **Diabetic Retinopathy Clinical Research Network**, “A Randomized Trial Comparing Intravitreal Corticosteroids and Laser Photocoagulation for Diabetic Macular Edema.” (August 2004 – 2007)

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Alcon C-05-62**, “A clinical evaluation of the safety and efficacy of preservative-free Triamcinolone Acetonide sterile suspension for visualization during vitreoretinal surgery.” (August 2007 – October 2007)

Principal Investigator: S. Young Lee, M.D.

Principal Investigator, **DRCR Protocol B**, “A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for DME.” (September 2004 – August 2008)

Sub-Investigator: S. Young Lee, M.D.

Principal Investigator, **EYETECH EOP1013**, “A phase 2/3, randomized, controlled, double-masked, multi-center, comparative dose-finding trial in parallel groups, to compare the safety and efficacy of intravitreal injections of 0.3, 0.03, 0.003mg Macugen, given as often as every 6 weeks for 3 years, to sham injections, in subjects with Diabetic Macular Edema involving the center of the macula.” (September 2005 – May 2007)

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **ALCON C0418**, “Clinical evaluation of the safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for use During Surgery for removal of epimacular membrane and vitrectomy.” (February 2006 – March 2007)

Principal Investigator: S. Young Lee, M.D.

Principal Investigator, **EYETECH EOP1012**, “A phase 3B/4, randomized, active-controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks plus sham Photodynamic Therapy to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.” (March 2005 – February 2007)

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Genaera Corporation MSI-1256F-208**, “A Phase 2, Multi-center, Randomized, Controlled, Masked Study of the Effects of Squalamine Lactate in Combination with Visudyne in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.” (December 2004 – 2005)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator, Genaera Corporation MSI-1256F-209, “A Phase 2, multi-center, Randomized, Masked, Controlled Study of the MSI-1256F (Squalamine Lactate) for Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.” (December 2004 – 2005)
Principal Investigator: S. Young Lee, M.D.

Principal Investigator, Eyetech EOP1011B, “A Phase II randomized, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO.” (August 2004 – 2005)
Sub-Investigator: S. Young Lee, M.D.

Strategic Clinical Research Group- Clinical Research Studies

Sub-Investigator, AiViva Biopharma Inc. AI007-E01-00, “A Phase I Study of the Safety, Pharmacokinetics, and Duration of Effect of Intravitreally Administrated AIV007 Gel Suspension in Subjects with Neovascular Age-Related Macular Degeneration.” (August 2020 – Present)
Principal Investigator: Ross Lynds, M.D.
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Amgen, Inc. 20170542, “A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration (hereinafter “Protocol”) ABP 938 (hereinafter “Study Drug”)” (May 2020– Present)
Principal Investigator: Ross Lynds, M.D.
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Genentech, Inc. GR4198 7 Rhone X, “A multicenter, open-label extension to evaluate the long term safety and tolerability of faricimab in patients with Diabetic Macular Edema.” (Sept 2020– Present)
Principal Investigator: S. Young Lee, M.D.
Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, Genentech, Inc. GR41984 Balaton, “A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion.” (July 2020– Present)

Principal Investigator: S. Young Lee, M.D.
Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, Genentech, Inc. GR41986 Comino, “A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion.” (July 2020– Present)
Principal Investigator: S. Young Lee, M.D.
Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, Genentech, Inc. MR41926 Altimeter, “A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA)” (2021– Present)
Principal Investigator: S. Young Lee, M.D.
Sub-Investigator: Ross Lynds, M.D.

Principal Investigator, IVERIC Bio., Inc. ISEE2008, “A phase 3 clinical study to further test the safety and efficacy of its proprietary drug candidate known as ZIMURA (avacincaptad pegol) in patients with geographic atrophy secondary to dry age-related macular degeneration.” (March 2020–Present)
Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Kodiak Sciences, Inc. KS301P103 BEACON, “A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)” (Sept 2020– Present)
Principal Investigator: Ross Lynds, M.D.
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Kodiak Sciences, Inc. KS301P104 Gleam, “A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)” (Sept 2020–Present)
Principal Investigator: Ross Lynds, M.D.
Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, NGM Biopharmaceuticals, Inc. NGM621-GA-201, “A Phase 2 multicenter, randomized, double-masked, sham controlled study of the safety and efficacy of intravitreal injections of NGM621 in subject with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration

(AMD)” (August 2020– Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, **Outlook Therapeutics, Inc. ONS-5010-002 Norse 2**, “A Clinical Effectiveness, Multi-center, Randomized, Double-Masked, Controlled Study of the efficacy and safety of ONS-2010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) to Secondary to Age-Related Macular Degeneration (AMD).” (March 2020 –Present)

Principal Investigator: Ross Lynds, M.D.

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Outlook Therapeutics, Inc. ONS-5010-003 Norse 3**, “A 3-month study to assess the safety of ONS-5010 in subjects with visual impairment due to retinal disorders, Norse three.” (Sept 2020– Feb 2021)

Principal Investigator: Ross Lynds, M.D.

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, **Regeneron Pharmaceuticals VGFTe-HD-DME-1934 Photon**, “A Randomized, double-masked, active-controlled Phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema- PHOTON” (August 2020– Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, **Roche TCRC, Inc. BP41321 Canberra**, “A randomized, double-masked, 48-week, parallel-group, Placebo controlled, Proof of Concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve Diabetic Retinopathy” (Feb 2020– Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, **Sam Chun Dang Pharm. Co., Ltd. SCD411-CP101**, “A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration” (October 2020– Present)

Principal Investigator-Ross Lynds, M.D.

Sub- Investigator: S. Young Lee, M.D.

Sub-Investigator, **Sandoz Inc. SOK583A1**, “A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration (the “*Trial*”)” (October 2020–Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, **Allergan Beacon 190342-038**, “Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System (PS DDS) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.” (May 2004 – November 2017)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, **Genentech Chroma GX29176**, “A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.” (November 2014 – 2018)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, **Genentech GX30191**, “A Phase III, Multicenter, Open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have completed a Roche-Sponsored Study.” (2016 – 2018)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, **Allergan Sequoia 150998-006**, “Safety and Efficacy of Abicipar Pegol (150998-006) in Patients with Neovascular Age-related Macular Degeneration.” (February 2016 – 2019)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, **Genentech Stairway GX39521**, “Stairway: Simultaneous blockade of angiopoietin-2 and Vegf-A with bispecific antibody RO6867461 (Rg7716) for extended durability in the treatment of Neovascular Age-Related Macular Degeneration.” (January 2017 – March 2018)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, Ophthotech OPH2007, “A Phase 2a open-label trial to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5 Mg in treatment naïve subjects with Neovascular Age-Related Macular Degeneration.” (February 2017 – July 2018)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Regeneron VGFTe-OD-1411, “A Phase 3, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy.” (February 2017 –2019)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Grant P. Janzen, M.D., Courtney Crawford, M.D.

Sub-Investigator, Aldeyra ADX-102-UV-005, “A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects with Non-Infectious Anterior Uveitis.” (August 2017 – 2018)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Allergan Maple 1771-201-008, “Evaluation of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.” (May 2018 – 2019)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Chengdu Kanghong Biotechnology Co., Ltd. Panda KHB-1801, “A multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration.” (August 2018 – Present)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Ophthotech Zimura OPH2003, “A Phase II/III randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura (Anti-C5 Aptamer) in subjects with Geographic Atrophy secondary to dry age-related Macular Degeneration.” (December 2017 – 2019)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Clearside Topaz CLS1003-302, “Topaz: A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA with intravitreal aflibercept in subjects with retinal vein occlusion.” (August 2018 – 2019)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Genentech, Inc. Yosemite GR40349, “A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to evaluate the efficacy and safety of RO6867461 in Patients with Diabetic Macular Edema.” (September 2018 – Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Ophthotech Zimura OPH2005, “A phase 2b randomized, double-masked, controlled trial to establish the safety and Efficacy of Zimura (Complement C5 Inhibitor) compared to sham subjects with Autosomal Recessive Stargardt Disease.” (December 2017 – 2020)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Opthea OPT-302-1002, “A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, inpatients with neovascular age-related macular degeneration (wet AMD)” (“Study”) in accordance with Sponsor’s protocol no. OPT-302-1002.” (January 2018 – 2019)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Opthea OPT-302-1003, “Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema.” (April 2018 – 2020)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Principal Investigator, Apellis OAKS APL2-304, “A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)” (2019 – Present).

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Genentech, Inc. Lucerne GR40344, “A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-Controlled Study to evaluate the efficacy and safety of fabricmab in patients with neovascular age-related macular degeneration (Lucerne)” (2019 – Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Gyroscope Therapeutics Limited GTSCOPE, “A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration” (2019 – Present)

Principal Investigator: Ross Lynds, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Sub-Investigator, Ionis Pharmaceuticals, Inc. ISIS 696844-CS5, “A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)” (2019-Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Ross Lynds, M.D.

Sub-Investigator, Kodiak Sciences Inc. KSI-CL-102, “A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-Related Macular Degeneration” (2019-Present)

Principal Investigator: Ross Lynds, M.D.

Sub-Investigator: S. Young Lee, M.D.

Sub-Investigator, Xbrane Biopharma XBR1001, “Xplore: A Phase III Double-Blind, Parallel Group, Multi-center Study to Compare the Efficacy and Safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration” (2019 – Present)

Principal Investigator: S. Young Lee, M.D.

Sub-Investigator: Courtney Crawford, M.D., Ross Lynds, M.D.

Sub-Investigator, Graybug Vision, Inc. GBV-102-002, “A Phase2b Multicenter Dose-Ranging Study Evaluating the Safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)” (2019-2021)

Principal Investigator: Courtney Crawford, M.D.

Sub-Investigator: S. Young Lee, M.D., Ross Lynds, M.D.

Abstracts

Kermani-Arab, V., **S.S. Patel**, J.L. Fahey, and A. Razzaque Ahmed. 1983. Interleukin 2 deficiency in pemphigus. *Clinical Research* 31:578A.

Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1987. Nonspecific cytotoxic potential of cloned human T lymphocytes. *Fed. Proc.* 46:476 (#931).

Parkey, R.T., D.L. Thiele, **S.S. Patel**, and P.E. Lipsky. 1988. Lack of a requirement for CD3/T cell receptor complex recognition in mediation of MHC-unrestricted cytotoxicity by activated T cells. *FASEB J.* 2: A463 (#975).

Patel, S.S., D.L. Thiele, and P.E. Lipsky. 1988. Human peripheral blood T cell clones exhibit multiple functional activities. *FASEB J.* 2: A476 (#1047).

Ritter, A.R., L.S. Davis, **S.S. Patel**, J.P. Atkinson, and P.E. Lipsky. 1988. An antiserum to decay-accelerating factor (DAF) activates human T cells. *FASEB J.* 2: A871 (#3347).

Geppert, T.D., M.C. Wacholtz, **S.S. Patel**, E. Lightfoot, and P.E. Lipsky. 1988. T cell activation by cross-linking class I major histocompatibility complex (MHC) molecules. *FASEB J.* 2: A1655 (#7888).

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1988. Cross-linking class I major histocompatibility complex (MHC) determinants stimulates human CD4+ and CD8+ T cell clones. *FASEB J.* 2: A1828 (#8897).

Thiele, D.L., **S.S. Patel**, and P.E. Lipsky. 1988. Anti-CD3 mediated regulation of MHC-unrestricted cytotoxicity by activated T cells: Lack of role for CD3/T cell receptor complex in tumor lysis. *Clinical Research* 36:449A.

Wacholtz, M.C., S.S. Patel, and P.E. Lipsky. 1989. LFA-1 as a signaling molecule. *Clinical Research*. 37:560A.

Patel, S.S., A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1989. Functional characterization of human peripheral blood CD3+CD4-CD8- and CD3+CD4+CD8+ T cell clones. *FASEB J.* 3: A515 (#1681).

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. LFA-1 (CD11a/CD18) as a signaling molecule in T cell activation. *FASEB J.* 3: A786 (#3349).

Kavanaugh, A., **S.S. Patel**, E. Lightfoot, P.E. Lipsky, and N. Oppenheimer-Marks. 1990. Delineation of the capacity of CD18 deficient T cells to bind to and migrate through endothelial cells. *FASEB J.* 4: A2054 (#2092).

Patel, S.S., B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation. *Amer. Acad. of Ophthalmology*.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Amer. Acad. Of Ophthalmology*.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Amer. Uveitis Society*.

Patel, S.S., N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. 1996. Initial clinical experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. *ARVO*. S257 (#1173).

Ge, N., **S. Patel**, D. Heuer, D. Minckler, and R. Varma. 1996. Initial clinical experience with the Ahmed glaucoma valve implant in the management of complicated glaucoma. *ARVO*. S258(#1179).

Kapusta, M., J.L. Marx, **S.S. Patel**, N.A. Rao, and L.P. Chong. 1996. The clinical outcome of high dose intravitreal ganciclovir in progressive outer retinal necrosis. *ARVO*. S371 (#1716).

Marx, J.L., M.A. Kapusta, **S.S. Patel**, F. Walonker, N.A. Rao, and L.P. Chong. 1996. The use of the ganciclovir implant in the treatment of recurrent CMV retinitis. ARVO. S669 (#3072).

Johnston, R.H., P. Lee, **S. Patel**, M. Kapusta, D.A. Frambach, and L.P. Chong. 1997. Management of neovascular glaucoma using combined pars plana vitrectomy and seton implant. ARVO.S769. (#3557).

Kapusta, M.A., R.L. Nguyen, R. Johnston, **S. Patel**, P. Lee, and L. Chong. 1997. Is a combined procedure of penetrating keratoplasty, vitrectomy, and seton implant in the pars plana effective? ARVO. S666 (#3123).

Patel, S.S., and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. AAO.

Patel, S.S., R. Anand, D. Callanan, and R. Leonard. 1999. Diabetic tractional retinal detachment: Anatomic and functional variables important in visual prognosis. AAO.

Patel, S.S., and S.Y. Lee. NAION. AAO 2006

Patel, S.S., and CRVO study. ARVO 2007

Boyer D S, Faber D, Gupta S, **Patel S S**, Tabandeh H, Li X Y, Liu C, Lou J, Whitcup S M, Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients: *Abstract Retina* 2011 May;31(5):915-23. Doi: 10.1097/IAE.0b013e318206d18c.

Patel, S.S., Nguyen, Q.D., D.M. Brown, D.M. Marcus, D.S. Boyer, L. Finer, A. Gibson, A.C. Rundle, J.J. Hopkins, R.G. Rubio, J.S. Ehrlich, and RISE and RIDE Research Group. 2012 Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. AAO.

Patel S, Peters C, Garcia K, Jaimes A, Miller B, Kymes S, Turpcu A. 2012. Truck Drivers Suffer Significant Economic Harm Due to Diabetic Macular Edema. *ARVO 2013 The Association for Research in Vision and Ophthalmology: Abstract*

Turpcu A, Peters C, **Patel S**, Garcia K, Jaimes A, Miller B, Kymes S. Economic Burden of Diabetic Macular Edema on Truck Drivers. *AMCP 2013 Academy of Managed Care Pharmacy: Abstract*

Rosenfeld P J, Slakter J S, Boyer D S, Brown D M, Chaudhry N A, Elman M J, **Patel S S**, O'Shaughnessy D. May 6, 2015. ARVO 2015 Annual Meeting – A Phase 1 Safety Study of an Orally Available Tyrosine Kinase Inhibitor X-82 in previously treated Wet AMD Patients: *Abstract*

Invited Lectures

Patel, S.S., B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation. Amer. Acad. of Ophthalmology.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Amer. Acad. of Ophthalmology.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Amer. Uveitis Society.

Patel, S.S. 1996. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency syndrome. Vanderbilt University Invited Lecture.

Patel, S.S. 1997. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency syndrome. University of Arkansas Invited Lecture.

Patel, S.S. 1998. Current management strategies for CMV retinitis. Southern Retinal Study Group. New Orleans, LA.

Patel, S.S. 1998. Evolution of macular hole surgery. Texas Tech University Alumni Lecture.

Patel, S.S. 1998. Evolution of macular hole surgery. Vanderbilt University Invited Lecture.

Patel, S.S., and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. Amer. Acad. of Ophthalmology

Patel, SS and S Y. Lee. 2006. American Academy of Ophthalmology. NAION.

Patel, S.S., Nguyen, Q.D., D.M. Brown, D.M. Marcus, D.S. Boyer, L. Finer, A. Gibson, A.C. Rundle, J.J. Hopkins, R.G. Rubio, J.S. Ehrlich, and RISE and RIDE Research Group. 2011. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. American Academy of Ophthalmology.

Presentations

Patel, S.S., B.F. Jost, and G.E. Fish. Peripapillary choroidal neovascularization: laser treatment versus observation. Doheny Alumni Day 1993.

Patel, S.S., R. Kruger, and R. Green. Are two intraocular lenses better than one? Doheny Alumni Day 1994.

Patel, S.S., A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Doheny Alumni Day 1994.

Patel, S.S., N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. Initial clinical experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. Doheny Alumni

Courses

Patel, S. S., R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments. AAO (1998).

Patel, S. S., R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments. AAO (1999).

Patel, S. S., R. Anand, D. Callanan, and R. Leonard. Surgical management of diabetic tractional retinal detachments. AAO (2000).